RESULTS:
Robust, dose-responsive HR to platelet lysate was observed in two of eight nulliparous, nevertransfused, healthy donors. No HR was observed with plasma. Among manipulated platelet lysates, only trypsin treatment significantly reduced HR (39% reduction; p 5 0.008). HR in response to platelet lysate significantly decreased with either cell surface immunoglobulin depletion or ibrutinib pretreatment. Platelet mitochondria induced minimal basophil HR, and DNase treatment did not inhibit platelet lysate-induced HR.
CONCLUSION: Type I immediate hypersensitivity to platelet proteins may be an allergic transfusion reaction mechanism. Prior sensitization to human proteins is not required for basophil responses to platelet proteins. Further study into the relative contributions of hypersensitivity to platelet versus plasma proteins in transfusion is warranted.
A llergic transfusion reactions (ATRs) are the most commonly reported severe transfusion reactions.
1,2 Antibody-mediated reactions with immunoglobulins specific to complement, haptoglobin, immunoglobulin (Ig)A, and IgE can cause ATRs, and passive transfer of IgE can result in delayed ATRs. 3 Collectively, however, these mechanisms are not prevalent enough to account for the high incidence of ATRs. 4 A commonly hypothesized ATR mechanism proposes that transfusion recipients harbor antibodies to donor proteins that elicit type 1 immediate hypersensitivity reactions. Indeed, removing donor plasma from blood components through a variety of methods reduces ATRs. 5, 6 These plasma-reduction methods support the concept that donor plasma proteins are allergens. However, removing plasma also reduces concentrations of other hypothesized mediators of ATRs, such as histamine, 7 cluster of differentiation ligand (CD40L), 8 chemokine (C-C motif) ligand 5 (CCL5), 9 ,10 lipid mediators, 11 microparticles, 12 mitochondrial DNA (mtDNA), and damage-associated molecular pattern proteins. 13, 14 Thus, various hypotheses invoke proteins, small molecules, mitochondria, or microparticles that may be derived from plasma or platelets and imply antibody-dependent or independent mechanisms. Studies to date have not directly compared these potential allergic mechanisms. In this study, we used a human basophil model 15 to test the hypothesis that soluble platelet proteins are a primary cause of ATRs.
MATERIALS AND METHODS
Platelet lysate and platelet-poor plasma preparation Figure S1 (available as supporting information in the online version of this paper) outlines the experimental concept. demonstrated that residual organic solvent in the aqueous phase was toxic to basophils. The bottom aqueous phase was subsequently dialyzed as described above. Thus, delipidation represents the combination of both delipidation and dialysis. Partially denatured platelet lysate was prepared on a heat block at 478C for 20 minutes. 17 Ultracentrifugation was done with a rotor (SW50.1, Beckman Coulter) at 200,000 3 g for 1 hour at 48C. Platelet lysate was trypsinized using immobilized TPCK trypsin (Thermo Scientific Pierce) at 378C for 18 hours.
Mitochondria preparation
Mitochondrial isolation was performed with anti-TOM22 beads (Miltenyi) from supernatant of 3 3 10 9 platelets that were chilled and repeatedly sheared through a 25-gauge needle 15 times. The final concentration of mitochondrial protein in each condition was 70 mg/mL. Platelet lysate and isolated mitochondria were treated with DNase (50 mg/mL) at 378C for 1 hour and stored at 2208C.
Basophil isolation
Whole blood was drawn from healthy donors according to an Institutional Review Board-approved protocol, in compliance with the Declaration of Helsinki. Basophil-enriched cell suspensions were prepared by using a double-Percoll gradient method. 18 Cells were suspended in Iscove's modified Dulbecco's medium supplemented with nonessential amino acids, penicillin/streptomycin, and 2% human AB serum at approximately 80 cells/mL. Before challenging, the cells were primed with 2 ng/mL recombinant human interleukin-3 (Shenandoah) for 15 minutes at 378C. A catalogue of the basophil donors that were used in experiments is provided in Table S1 (available as supporting information in the online version of this paper).
Human basophil HR assay
Basophil HR was measured in response to platelet component derivatives (platelet component supernatant [plasma] at 5 mg/mL and cleared platelet lysate at three concentrations [2.5, 5, and 10 mg/mL final concentration]), and manipulated platelet lysates were examined to characterize the unknown allergic stimuli. Two thousand basophils were added to each experimental condition: positive controls of 2 mg/mL goat antihuman IgE (ICL) or 0.1 mM Nformylmethionine-leucyl-phenylalanine (fMLP) (Sigma), platelet lysates, or PPP were suspended in 25 mL buffer (25 mM piperazine-N,N 0 -bis [PIPES], 0.003% human serum albumin, 0.1% glucose, 110 mM NaCl, 5 mM KCl, 1.5 mM CaCl2, and 1 mM MgCl2, pH 7.3). Anti-IgE cross-links IgE to nonspecifically activate basophils, and fMLP activates basophils through an IgE-independent, G protein-coupled receptor pathway. All except for total histamine samples were incubated on a heat block at 378C for 45 minutes, and 300 mL of cold EDTA buffer (25 mM PIPES, 110 mM NaCl, 5 mM KCl, 0.003% human serum albumin, 0.1% glucose, and 10 mM EDTA, pH 7.3) was added at completion. Subsequently, samples were centrifuged at 400 3 g for 3 minutes, and 250 mL of each supernatant was collected. HR was measured by ELISA (Cayman Chemical or Beckman Coulter) and compared with total histamine content. Because platelets contain histamine, platelet lysate histamine content was tested with each experiment and subtracted from histamine concentrations released in basophil experiments. The average histamine concentration at the highest platelet lysate concentration (i.e., 10 mg/mL) represented 3.4% of the total basophil histamine content measured in each experiment.
In select experiments aimed at evaluating the immunoglobulin dependence of ATRs, lactic acid dissociation of basophil cell surface immunoglobulins was performed according to the method described by Pruzanksy and coworkers 19 ; in other experiments, immunoglobulin signaling was inhibited with 50 nM ibrutinib (APExBio) either in dimethyl sulfoxide or in dimethyl sulfoxide alone as a control at 378C for 15 minutes. Immunoglobulin signaling, including IgE signaling after contact with allergen, utilizes Bruton's tyrosine kinase (BTK), which ibrutinib specifically inhibits. 20 Plasma from a patient included in our prior study 4 was used as a source immunoglobulin and incubated with immunoglobulin-stripped basophils. This patient's plasma was selected because of a known history of multiple ATRs to platelets and a history of Kentucky blue grass allergy. This plasma was also subjected in parallel to a protein L agarose spin column (GE SpinTrap) to selectively remove immunoglobulin, including IgE.
Specific IgE testing
Plasma from basophil donors was screened for aeroallergen-specific IgE using the Phadia ImmunoCAP system (ThermoFisher Scientific) with allergen mixes WX1 (Ambrosia artemisiifolia, Artemisia vulgaris, Plantago lanceolata, Chenopodium album, Salsola kali), GX1 (Dactylis glomerata, Festuca elatior, Lolium perenne, Phleum pratense, Poa pratensis), and TX1 (Acer negundo, Betula verrucosa, Quercus alba, Ulmus americana, Juglans californica). The results are reported as positive or negative according to the manufacturer's cutoff.
Statistics
Comparisons of HR between groups were made using the Wilcoxon signed-rank test with Stata software (version 13.1; StataCorp). p values less than 0.05 were considered statistically significant. Figure 1 shows the basophil HR caused by platelet lysate compared with plasma in healthy volunteers (n 5 8). Platelet lysate induced more HR than plasma at the same protein concentration. At concentrations of 2.5, 5, and 10 mg/ mL, platelet lysate induced a median increase in HR by 15%, 53%, and 61%, respectively. Basophils from Donors 4 and 8 exhibited the greatest dose-responsive HR to platelet lysate. Both donors were nulliparous, transfusion-naive, healthy individuals (Table 1) . Although these donors had the greatest reactivity, Donors 1, 2, 3, and 7 ( Fig. 1) had some degree of reactivity to platelet constituents.
RESULTS
To correlate basophil responses with allergic phenotype of the basophil donors, we asked donors about their allergic history and performed screening for specific IgEs to grass, weed, and tree allergens, the most common allergy triggers (Table 1) . There was no association between reactivity to platelets in the basophil activation test and an atopic history or the presence of aeroallergen-specific IgE.
Cleared platelet lysate is a complex mixture of microparticles, proteins, lipids, and small molecules; and the observed reactivity illustrated in Fig. 1 could be caused by one or several of these constituents. We modified the platelet lysate to be deficient in microparticles, proteins, lipids, and small molecules and ascertained the relative contribution of each of these components to the observed HR. We performed experiments using modified platelet lysates and compared them with the HR of unmodified platelet lysate (Fig. 2) . Trypsin treatment of platelet lysate reduced HR by 39% (p 5 0.008), and delipidation of platelet lysate decreased HR by 20% (p 5 0.051). When evaluating results only from the two highly reactive donors, the average reduction was greatest with trypsinization (59% reduction), followed by delipidation/dialysis (49% reduction), dialysis (33% reduction), ultracentrifugation (21% reduction), and heat denaturation (18% reduction).
Next, we tested whether the basophil activation was immunoglobulin-dependent. Using basophils from a reactive basophil donor (Donor 4), we blocked IgE-mediated basophil activation with the BTK inhibitor ibrutinib (Fig.  3A) . Ibrutinib inhibited platelet lysate-induced HR by an average of 35% across platelet lysate concentrations, indicating an immunoglobulin-mediated response.
To further implicate IgE in basophil activation in response to platelet lysate exposure, we tested HR to platelet lysate after IgE was dissociated from the basophil cell surface and resensitized with third-party immunoglobulins 19 (Fig. 3B) . Unreactive healthy donor basophils (Donor 5 in Fig. 1 ) were loaded with immunoglobulins from the plasma of a previously reported patient 4 who had a history of two urticarial reactions after two platelet transfusions. The patient was also strongly IgE-positive against multiple aeroallergens, including Kentucky blue grass (data not shown). Figure 3B shows that reactivity to platelet lysate was transferred to donor basophils. Furthermore, HR in response to platelet lysate was decreased by an average of 59% across platelet lysate concentrations when immunoglobulin was removed from plasma before loading onto donor basophils. Finally, we tested the contribution of mitochondria and cell-free DNA to HR. Figure 4 indicates that HR to platelet lysate was maintained with DNase treatment and that isolated mitochondria were relatively weak activators of basophils, with an average 34% increase in HR over buffer control compared with platelet lysate, which induced a 315% increase in HR over buffer control in the same experiment. 
DISCUSSION
This study identifies Type 1 immediate hypersensitivity to platelet proteins as a mechanism for ATRs. Specifically, we provide evidence that HR was reduced with trypsin treatment of platelet lysate and immunoglobulin removal from the basophil surface. HR was unchanged when microparticles or small molecules were removed or when DNase was added. Platelet granule contents have been proposed as mediators of ATRs. 21 Because dialysis treatment of Plasma contains platelet-derived proteins, which may be responsible for some ATRs to plasma. Indeed, ATR rates are higher to platelet components than to plasma components. 1 Greening and colleagues identified 41 platelet proteins in the human plasma proteome. 22 It is also known that platelet microparticles are shed into plasma, 23 although our data suggest that microparticles do not cause significant HR. ATRs are frequent in nulliparous transfusion recipients with a first transfusion. 24 Similarly, the two reactive healthy donors in this study had no prior sensitization event. The development of this innate susceptibility is not yet understood but may involve epitope semblance between human platelet proteins and other allergens, of which there is one example. 25 Alternatively, there may be a protein or protein modification that can nonspecifically activate FceR1 (high-affinity IgE receptor). Both hypotheses are consistent with our results. Volunteers in this study had various patterns of reactivity in the basophil activation test, underscoring the heterogeneity of allergic responses across individuals. Basophil Donors 3 and 5 ( Fig. 1 ) reacted minimally to all stimuli. Donors 1 and 7 reacted strongly to positive controls, but not to platelet constituents. Donors 4 and 8 reacted strongly to all stimuli except plasma. A medical history of atopy was not associated with basophil reactivity, despite previous results indicating that individuals who have ATRs are more likely to have aeroallergies (hay fever). 4, 26 This finding suggests either that basophils are not an accurate model of ATRs or that a diagnosis of hay fever is weakly associated with ATR risk. Indeed, hay fever is a prevalent disease, and 19% of individuals who have never had an ATR to platelet transfusion have had a confirmed diagnosis of hay fever. 4 The 25% prevalence of reactive basophil donors in this study (two of eight donors) may appear to be high compared with the 2% incidence of ATRs to platelet transfusion 27 ; however, it should be noted that ATR incidence is measured on a per-transfusion basis. A prior cohort study 28 demonstrated that, when analyzed over the entire transfusion history, 53% of platelet recipients experience at least one ATR.
mtDNA and proteins have recently emerged as candidates for ATR mediators.
14 However, our model suggests that they do not completely explain basophil HR in response to platelet proteins. Two reports indicate that mtDNA is elevated in acute transfusion reactions, but concentrations do not markedly differ among different types of acute transfusion reactions. 13, 21 If mitochondria cause ATRs, then it remains to be determined how mitochondria can elicit a wide array of inflammatory manifestations.
There are limitations to this study. First, mast cells are the primary allergic effector cell type, not basophils. Although basophils share many features of mast cells, they do not exactly recapitulate mast cell activation. 29 
Many
ATRs occur in basopenic patients receiving cytotoxic chemotherapy. In these patients without basophils, ATRs are more likely mediated by mast cells; however, testing of human primary mast cells from patients with ATRs is not feasible. Second, this study focused on recipient susceptibility to ATRs. There may be donor or storage conditions that contribute to ATRs. 28 Knowing the specific platelet protein(s) responsible for ATRs will help elucidate the donorrelated and storage-related causes of ATRs. Third, we only evaluated basophil responses to eight donors. Larger studies are needed to estimate the prevalence of reactivity to plasma and platelet proteins. Fourth, this study does not address the potential of multiple factors causing HR-alone, some may cause minimal changes in basophil activity, but, simultaneously, they can cause a significant change. In vitro HR is a surrogate for complex in vivo allergic reactions that have been demonstrated to involve prostaglandins, leukotrienes, histamine, 4, 30 and likely also platelet-activating factor. 31 The relative contributions of these mediators to clinical ATRs remain to be determined. Future studies could assess basophil reactivity to the transfused products from the very patients and products involved in clinical reactions; however, most platelet recipients are basopenic from myelotoxic chemotherapy. Studying ATRs in nonleukopenic patients chronically receiving red blood cell transfusions may be a more feasible approach. Having implicated platelet proteins as a cause of ATRs, exposing basophils to various platelet protein fractions in an HR model may further define the set of proteins that cause ATRs. In summary, Type I immediate hypersensitivity to platelet proteins is a mechanism for ATRs. Small molecules, microparticles, and mitochondria are not significant contributors to ATRs in this human basophil model. Prior sensitization to human proteins is not required for reactivity. 
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article at the publisher's website. Fig. S1 . Experimental concept for basophil activation testing. (A) Potentially allergenic sources in plasma and platelets are incubated with basophils from healthy volunteers to elicit histamine release. (B) Apheresis platelet components (n54) were separated into platelet poor plasma (PPP) and platelet fractions. Platelets were then washed, sonicated, and a portion was manipulated further to achieve the desired experimental condition (indicated by microcentrifuge tube). Table S1 . Listing of basophil donors used in experiments.
